Efficacy of methylprednisolone pulse therapy for acute relapse in Japanese patients with multiple sclerosis and neuromyelitis optica: A multicenter retrospective analysis – 1. Whole group analysis. Issue 3 (21st November 2013)

• Record Type: Journal Article
• Authors: Kira, Jun‐ichi; Yamasaki, Ryo; Yoshimura, Satoshi; Fukazawa, Toshiyuki; Yokoyama, Kazumasa; Fujihara, Kazuo; Ogino, Mieko; Yokota, Takanori; Miyamoto, Katsuichi; Niino, Masaaki; Nomura, Kyoichi; Tomioka, Ryo; Tanaka, Masami; Kawachi, Izumi; Ohashi, Takashi; Kaida, Kenichi; Matsui, Makoto; Nakatsuji, Yuji; Ochi, Hirofumi; Fukaura, Hikoaki; Kanda, Takashi; Nagaishi, Akiko; Togo, Kanae; Mizusawa, Hidehiro; Kawano, Yuji
• Is Part Of: Clinical & experimental neuroimmunology. Volume 4:Issue 3(2013)
• Page Start: 305
• Page End: 317
• Publication Date: 2013-11-21
• Subjects: 616.80479
• DOI: 10.1111/cen3.12071
• Languages: English
• ISSNs: 1759-1961

Abstract

<abstract abstract-type="main" id="cen312071-abs-0001"> <title>Abstract</title> <sec id="cen312071-sec-0001" sec-type="section"> <title>Objectives</title> <p>There has been no large‐scale study of methylprednisolone pulse therapy in Asian patients with multiple sclerosis (MS) or neuromyelitis optica (NMO), despite it being widely used for acute relapse. We aimed to clarify treatment response of MS and NMO patients to methylprednisolone pulse therapy and post‐pulse oral corticosteroids in real clinical practice in a multicenter study in Japan.</p> </sec> <sec id="cen312071-sec-0002" sec-type="section"> <title>Methods</title> <p>Investigators at 28 institutions collected changes in neurological symptoms/signs and Expanded Disability Status Scale (EDSS) scores before and within 1 week of completion of methylprednisolone pulse therapy carried out in 2010, and after post‐pulse oral corticosteroids therapy, by retrospective review of medical records.</p> </sec> <sec id="cen312071-sec-0003" sec-type="section"> <title>Results</title> <p>In 345 patients (95.1% of all registered patients), 457 series of methylprednisolone pulse therapy were carried out for treatment of acute relapse. EDSS scores improved by 0.8 ± 1.1 (mean ± SD) after the first course. The second and third courses also produced sufficient improvements (by 0.7 and 0.6, respectively), but much smaller improvements were observed thereafter. The target neurological symptoms and signs improved in 79.5% of patients. Improvement rates were 5–20% lower after a course of pulse therapy than after a series of pulse therapy. A half dose (500 mg/day) produced less improvement than a standard dose (1000 mg/day; 65.9 <italic>vs</italic> 79.5%). During post‐pulse oral corticosteroid therapy, EDSS scores decreased by 0.6 ± 0.9. No significant adverse effects were observed.</p> </sec> <sec id="cen312071-sec-0004" sec-type="section"> <title>Conclusions</title> <p>Methylprednisolone pulse therapy is beneficial in nearly 80% of Japanese MS and NMO patients, and EDSS score improvements after therapy are compatible with those in Western MS patients.</p> </sec> </abstract>